ABSTRACT

Aims/Objective: To evaluate and characterized RGD sequenced fibrin/fibrinogen based nanoscaffolds (acid-labile linker) for the treatment of brain tumor targeting using u-87MG cell lines. Place and Duration of Study: Department of Pharmaceutics, Parul Institute of Pharmacy and Research, Parul University, Vadodara, between 2017 to 2021. Methodology: Nanoscaffolds was prepared with Drug–linker–Fbg conjugate solution, using modified water-in-oil (W/O) emulsification/solvent extraction method. The conjugate solution was evaluated with the molecularly targeted compound and assessed the effect of Everolimus on the cell lines; “gene or protein measurement” referred to studies that measured levels of molecular markers in response to Everolimus. Cell viability was the outcome of interest of the carried-out research work. Data on cell viability included the assay, quantification technique used and cell viability measurement. Results: MTT assay has been performed on formulation for assessing the % viability of the drug on U-87 MG cell line. Comparison of API with Formulation revealed that the formulation produces less cell viability as compared to individual API. The absorbance of the produced formazan is proportional to the number damaged or dying cells. Conclusion: As per the study design the formulated nanoscaffolds cell viability for formulation (50?g/ml) was studied which refers to the ability of a cell to perform its biochemical and physiological processes, particularly in regards to its metabolism and ability to divide that shows the lower effect of the IC50, which suggests the more cytotoxic the drug is to that specific cancer cell type. Keywords: Everolimus, Nanoscaffolds, U-87MG
Publication date: 01/08/2023

https://ijbpas.com/pdf/2023/August/MS_IJBPAS_2023_7363.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.8.7363